U.S. markets closed

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.43-0.84 (-3.46%)
At close: 4:00PM EDT

Avidity Biosciences, Inc.

10975 North Torrey Pines Road
Suite 150
La Jolla, CA 92037
United States
858 401 7900

Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Dr. Troy Edward WilsonCo-Founder & Chairman132kN/A1969
Ms. Sarah BoycePres, CEO & Director823.09kN/A1972
Mr. Michael F. MacLeanChief Financial Officer501.34kN/A1966
Prof. Mark E. DavisScientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.sN/AN/AN/A
Dr. Frank McCormick Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/A1950
Mr. Joseph BaroldiChief Operating OfficerN/AN/A1978
Dr. W. Michael Flanagan Ph.D.Chief Technical OfficerN/AN/A1962
Dr. Arthur A. LevinChief Scientific OfficerN/AN/A1954
Dr. John W. Wallen IIIVP of Intellectual Property, Gen. Counsel & Sec.N/AN/A1958
Ms. Teresa McCarthyChief HR OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.

Corporate Governance

Avidity Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.